Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus SIMPESSE.
CYCLESSA vs SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Oral: 10 mg once daily, taken at least 1 hour before a meal.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive